ReviewBlood2015
The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.
Review in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05262881 (A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Pooled it
- Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy.International journal of hematology · 2016Trial
- Epidemiology, therapy, and outcome of immune-mediated thrombotic thrombocytopenic purpura at population level in Germany.Research and practice in thrombosis and haemostasis · 2026Article
- Acquired immune-mediated thrombotic thrombocytopenic purpura with severe cholestatic liver injury and reversible acute kidney injury after ivonescimab-containing chemoimmunotherapy: a case report and literature review.Frontiers in immunology · 2026Review
- A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021.Journal of clinical apheresis · 2025Article
- Experience in emergency management of first-episode immune thrombotic thrombocytopenic purpura over the past 21 years: a single-center retrospective study.Frontiers in immunology · 2025Article
- Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study.Journal of clinical medicine · 2024Article
- Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura.Blood transfusion = Trasfusione del sangue · 2023Article
- Clinical Features and Risk Factors of Relapse and Mortality in Thrombotic Thrombocytopenic Purpura Patients: A Seven-Year Experience.International journal of hematology-oncology and stem cell research · 2023Article
- Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report.Cureus · 2023Article
- Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship.Frontiers in medicine · 2023Review
- Article
- TTP: From empiricism for an enigmatic disease to targeted molecular therapies.British journal of haematology · 2022Review
- An Update on COVID-19 Vaccine Induced Thrombotic Thrombocytopenia Syndrome and Some Management Recommendations.Molecules (Basel, Switzerland) · 2021Review
- Silent Thrombotic Thrombocytopenic Purpura: PLASMIC, Lessons Learned, and Current Management Overview.Cureus · 2021Article
- Fluctuating neurological symptoms: should I call the neurologist or the hematologist?Advances in laboratory medicine · 2021Article
- Humanized anti CD-20 as an alternative in chronic management of relapsing thrombotic thrombocytopenic microangiopathy resistant to rituximab due to anti chimeric antibody.International journal of hematology · 2021Article
- Clínica neurológica fluctuante: ¿Llamo al neurólogo o al hematólogo?Advances in laboratory medicine · 2021Article
- Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.Therapeutics and clinical risk management · 2021Review
- Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan.International journal of hematology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.